To put our results in perspective, we compared them to three other screening tools commonly used in clinical practice: the prostate-specific antigen (PSA) and digital rectal exam (DRE) for prostate cancer and mammography for breast cancer. This evidence concerns the gene KLK3 and prostate carcinoma.